PALVELLA THERAPEUTICS, INC. 8-K

What Happened
Palvella Therapeutics, Inc. announced on June 29, 2026 that its Board increased from seven to eight members and appointed Matthew Pauls as a Class I director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders. The appointment was made upon the Nominating and Corporate Governance Committee’s recommendation and Mr. Pauls has been designated independent under applicable Nasdaq rules.

Key Details

• Appointment Date: June 29, 2026; initial term ends at the 2027 Annual Meeting.
• Board size: increased from seven to eight directors.
• Compensation: under the Company’s Non‑Employee Director Compensation Policy, Mr. Pauls will receive the standard annual retainer and was granted an option to purchase 6,000 shares of common stock, vesting in equal monthly installments over 36 months, subject to continued service.
• Background: Mr. Pauls (age 56) is CEO of Savara, Inc. since Dec 2020 and has prior senior roles at Strongbridge, Insmed, Shire, Bristol‑Myers Squibb and J&J; he serves on several boards and holds a B.S., an M.B.A., and a J.D.
• Governance: No related‑party transactions or family relationships requiring Item 404 disclosure; Board has determined Mr. Pauls is independent.

Why It Matters
This is a board-level governance update that adds an industry veteran with commercial and biopharma leadership experience to Palvella’s board. For investors, key takeaways are the company’s move to expand board expertise, the standard non‑employee director pay package (including a 6,000‑share option with a 3‑year vesting schedule), and the formal independence determination—facts that affect oversight and corporate governance but do not directly change operations or financials.